US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith
  
Number step 1, 2, 3 graphical representation of the process
The AAM CEO suggested the FDA take a more step-wise approach to its new ANDA pilot. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Interviews

More from US FDA